Financials Duopharma Biotech

Equities

End-of-day quote BURSA MALAYSIA Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
1.21 ^MYR	-1.63%		0.00%	-3.97%

05-01	Duopharma Biotech Clinches MYR578 million Supply Deals	MT
03-20	Duopharma Biotech Berhad Announces the Appointment of Mohd Haris Bin Mohd Arshad as Non Independent and Non Executive Member of Nomination and Remuneration Committee	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	971.8	2,386	1,582	1,533	1,212	1,164	-	-
Enterprise Value (EV) ¹	971.8	2,386	1,582	1,375	941.5	997.6	1,001	1,164
P/E ratio	17.2 x	40 x	24.1 x	21.8 x	23 x	14.2 x	12 x	11 x
Yield	4.23%	1.92%	1.37%	1.43%	1.83%	1.78%	2.15%	2.07%
Capitalization / Revenue	1.69 x	4.19 x	2.48 x	2.2 x	1.72 x	1.51 x	1.4 x	1.31 x
EV / Revenue	1.69 x	4.19 x	2.48 x	1.97 x	1.34 x	1.29 x	1.21 x	1.31 x
EV / EBITDA	9.45 x	21.8 x	13.1 x	10.7 x	7.58 x	6.32 x	5.68 x	6.18 x
EV / FCF	62 x	159 x	-24.4 x	295 x	62 x	5.8 x	20 x	17.1 x
FCF Yield	1.61%	0.63%	-4.1%	0.34%	1.61%	17.2%	5%	5.84%
Price to Book	1.84 x	3.71 x	2.55 x	2.33 x	1.77 x	1.51 x	1.39 x	1.23 x
Nbr of stocks (in thousands)	912,511	941,369	941,774	952,240	961,942	961,942	-	-
Reference price ²	1.065	2.535	1.680	1.610	1.260	1.210	1.210	1.210
Announcement Date	13/02/20	22/02/21	15/02/22	23/02/23	22/02/24	-	-	-

¹MYR in Million²MYR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	576.5	569.9	639.2	696.7	704.7	772.1	828.8	888.4
EBITDA ¹	102.8	109.5	120.8	129	124.2	157.9	176	188.4
EBIT ¹	77.64	81.86	88.76	92.91	81.14	116.8	132	144.5
Operating Margin	13.47%	14.36%	13.89%	13.34%	11.51%	15.12%	15.93%	16.27%
Earnings before Tax (EBT) ¹	70.81	76.16	82.98	84.85	63.27	103.7	120.2	133.4
Net income ¹	55.27	58.61	65.68	70.11	52.64	83.8	96.35	106.5
Net margin	9.59%	10.28%	10.28%	10.06%	7.47%	10.85%	11.63%	11.98%
EPS ²	0.0619	0.0634	0.0698	0.0739	0.0549	0.0852	0.1012	0.1100
Free Cash Flow ¹	15.67	14.98	-64.91	4.658	15.19	172	50	68
FCF margin	2.72%	2.63%	-10.15%	0.67%	2.16%	22.28%	6.03%	7.65%
FCF Conversion (EBITDA)	15.25%	13.68%	-	3.61%	12.23%	108.95%	28.4%	36.09%
FCF Conversion (Net income)	28.35%	25.56%	-	6.64%	28.86%	205.25%	51.89%	63.87%
Dividend per Share ²	0.0450	0.0488	0.0230	0.0230	0.0230	0.0215	0.0260	0.0250
Announcement Date	13/02/20	22/02/21	15/02/22	23/02/23	22/02/24	-	-	-

¹MYR in Million²MYR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	-	-	-	158	271	166	163	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	15.7	15	-64.9	4.66	15.2	172	50	68
ROE (net income / shareholders' equity)	10.9%	9.99%	10.4%	11%	7.84%	11.7%	12.3%	12.4%
ROA (Net income/ Total Assets)	6.29%	5.92%	5.65%	5.88%	4.1%	5.75%	6.75%	6.95%
Assets ¹	878.2	989.4	1,163	1,192	1,284	1,457	1,427	1,532
Book Value Per Share ²	0.5800	0.6800	0.6600	0.6900	0.7100	0.8000	0.8700	0.9800
Cash Flow per Share ²	-	-	0.0500	0.0700	0.0500	0.1000	0.1200	-
Capex ¹	51.3	56.4	114	65.1	30.6	51.5	70.6	58.5
Capex / Sales	8.91%	9.9%	17.8%	9.35%	4.34%	6.67%	8.52%	6.59%
Announcement Date	13/02/20	22/02/21	15/02/22	23/02/23	22/02/24	-	-	-

¹MYR in Million²MYR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.21 MYR

Average target price

1.475 MYR

Spread / Average Target

+21.90%

	1st Jan change	Capi.
DUOPHARMA BIOTECH	-3.97%	247M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.28%	43.92B
OTSUKA HOLDINGS CO., LTD.	+24.47%	23.09B
SANDOZ GROUP AG	+19.22%	15.35B
CIPLA LIMITED	+12.87%	13.61B
ZYDUS LIFESCIENCES LIMITED	+44.67%	12.02B
ONO PHARMACEUTICAL CO., LTD.	-9.92%	7B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.6B